Research progress in thyroid hormone replacement therapy for low T3 syndrome
10.3760/cma.j.cn101721-20220825-000385
- VernacularTitle:甲状腺激素替代治疗低T3综合征的研究进展
- Author:
Juan LI
1
;
Jingjing QI
;
Rong WU
Author Information
1. 中部战区总医院干部病房一科，武汉 430070
- Keywords:
Low triiodothyronine syndrome;
Thyroid Hormone;
Hormone replacement therapy
- From:
Clinical Medicine of China
2022;38(6):504-508
- CountryChina
- Language:Chinese
-
Abstract:
Low triiodothyronine syndrome (LT3S) is an abnormal alteration of thyroid hormone levels in patients with acute and severe illnesses in certain disease states, without clinical symptoms corresponding to altered thyroid function. There is a clear correlation between LT3S and the severity of the patient's condition and prognosis. The lower the triiodothyronine (T3) level is, the more severe the patient's condition is, and combined with acute physiology and chronic health score and other indicators, it can predict the prognosis of the patient's condition. The mechanism of occurrence and development of LT3S is relatively complex. In the early stage, it may be the adaptive change of the body to the stress condition. With the aggravation and extension of the disease course, it may participate in the disease progression.Current guidelines mostly do not recommend hormone replacement therapy (HRT) for patients with LT3S. New and more unified observational indicators should be available to fully verify the effectiveness of TH therapy.
